Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31467551 | 0.72 | EPHX1 (0.64) | HTTSMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL14344290 | 0.72 | HTT (0.49) | HTTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL31290295 | 0.72 | HTT (0.77) | HTTTSHRSMN1; SMN2ALDH1A1MMP2 | |
| SCHEMBL2352832 | 0.71 | TSHR (0.55) | HTTTSHRSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL11530961 | 0.70 | HTT (0.42) | HTTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL25087402 | 0.69 | HPGD (0.50) | HTTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL13528392 | 0.69 | HTT (0.45) | HTTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL16088178 | 0.69 | KMT2A (0.54) | HTTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL19176808 | 0.69 | KDM4E (0.50) | HTTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL162819 | 0.69 | KDM4E (0.50) | HTTTSHRSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015028513-A1 | ANTIMICROBIAL COATINGS | BASF SE (DE) | 2015-03-05 | — | — | WO | disclosed |
| US-8742003-B2 | Silylated amino resins | BASF SE (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20140066552-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8657947-B2 | Silylated amino resins | BASF SE (DE) | 2014-02-25 | — | — | US | disclosed |
| EP-2675830-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8541320-B2 | Silylated amino resins | BASF SE (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20130035435-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2013-02-07 | — | — | US | disclosed |
| US-20130005204-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130000516-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2536773-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8309649-B2 | Silylated amino resins | BASF SE (DE) | 2012-11-13 | — | — | US | disclosed |
| WO-2012110926-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2012-08-23 | — | — | WO | disclosed |
| US-20110213068-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011101301-A1 | SILYLATED AMINO RESINS | BASF SE (DE) | 2011-08-25 | — | — | WO | disclosed |
| EP-0758325-B1 | A PROCESS FOR PREPARING ISOCYANATE AND ISOCYANATE-BASED DERIVATIVES OF CERTAIN AMINO-1,3,5-TRIAZINES BY DIRECT PHOSGENATION | CYTEC TECH CORP (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-0758325-A1 | A PROCESS FOR PREPARING ISOCYANATE AND ISOCYANATE-BASED DERIVATIVES OF CERTAIN AMINO-1,3,5-TRIAZINES BY DIRECT PHOSGENATION | CYTEC TECHNOLOGY CORP. (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5556971-A | Process for preparing isocyanate and isocyanate-based derivatives of certain amino-1,3,5-triazines by direct phosgenation | CYTEC TECHNOLOGY CORP. (US) | 1996-09-17 | — | — | US | disclosed |
| WO-1995030663-A1 | A PROCESS FOR PREPARING ISOCYANATE AND ISOCYANATE-BASED DERIVATIVES OF CERTAIN AMINO-1,3,5-TRIAZINES BY DIRECT PHOSGENATION | CYTEC TECHNOLOGY CORP. (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130000516-A1 | SILYLATED AMINO RESINS | BCAT1, BCAT2, NPEPPS | HTT 1404/4885TSHR 4196/4885SMN1; SMN2 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.